GENE ONLINE|News &
Opinion
Blog

Will Biden’s Biomanufacturing Initiative Kill Korean Partnership?

by Max Heirich
Share To
The Biden Administration issued an executive order in September centered on bolstering the United States’ biomanufacturing capabilities. The administration intends the initiative to reduce the United States’ reliance on China for pharmaceuticals. However, this wide-ranging initiative has wide-ranging effects, namely on that of Korea’s Biotech Firms.  With companies like Samsung Biologics and SK Bioscience, Korea is one of the leaders in global CMO and CDMO supply chain, while some officials in Korea remain unfazed by the initiative or even see a benefit to the situation, others remain unconvinced. Contract manufacturing organizations (CMOs) or contract development and manufacturing organizations (CDMOs) are on alert as to whether or not Biden’s efforts to keep China in check will disadvantage them or not. 

GO Prime with only $1.49 now

LATEST
BIODND – An AI-Powered Database That Breaks New Ground in Life Science Business Development
2023-11-29
GeneOnline’s Weekly News Highlights: Nov 20-Nov 24
2023-11-27
SK Bioscience and Hilleman Laboratories Join Forces for Ebola Vaccine Development
2023-11-23
BeiGene to Expand Oncology Pipeline Through ENSEM Therapeutics Partnership
2023-11-23
Advancing the Frontiers of Cell and Gene Therapy – An Interview with Dr. Shin Kawamata
2023-11-21
Astellas and Pfizer’s Drug Receives FDA Approval as Treatment for High-Risk Prostate Cancer Recurrence
2023-11-21
GeneOnline’s Weekly News Highlights: Nov 13-Nov 17
2023-11-20
EVENT
2023-11-30
2023 Healthcare+ EXPO・Taiwan
Taipei , Taiwan
Scroll to Top